Guggenheim Capital LLC Karuna Therapeutics, Inc. Transaction History

Guggenheim Capital LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$161.01 - $317.85 $92,258 - $182,128	-573 Reduced 8.11%	6,495 $2.06 Million
Q3 2023 Nov 14, 2023	BUY	$164.66 - $218.08 $56,807 - $75,237	345 Added 5.13%	7,068 $1.2 Million
Q2 2023 Aug 11, 2023	SELL	$176.32 - $240.22 $33,148 - $45,161	-188 Reduced 2.72%	6,723 $1.46 Million
Q1 2023 May 10, 2023	SELL	$161.33 - $204.36 $675,327 - $855,450	-4,186 Reduced 37.72%	6,911 $1.26 Million
Q4 2022 Feb 14, 2023	BUY	$191.53 - $236.82 $389,763 - $481,928	2,035 Added 22.46%	11,097 $2.18 Million
Q3 2022 Nov 14, 2022	SELL	$123.79 - $277.42 $53,601 - $120,122	-433 Reduced 4.56%	9,062 $2.04 Million
Q2 2022 Aug 15, 2022	SELL	$93.97 - $143.33 $54,032 - $82,414	-575 Reduced 5.71%	9,495 $1.2 Million
Q1 2022 May 16, 2022	BUY	$98.9 - $132.37 $54,296 - $72,671	549 Added 5.77%	10,070 $1.28 Million
Q4 2021 Feb 14, 2022	BUY	$110.64 - $159.4 $45,583 - $65,672	412 Added 4.52%	9,521 $1.25 Million
Q3 2021 Nov 15, 2021	SELL	$101.2 - $125.87 $21,454 - $26,684	-212 Reduced 2.27%	9,109 $1.11 Million
Q2 2021 Aug 13, 2021	BUY	$107.45 - $135.95 $45,773 - $57,914	426 Added 4.79%	9,321 $1.06 Million
Q1 2021 May 13, 2021	BUY	$95.46 - $133.08 $404,941 - $564,525	4,242 Added 91.17%	8,895 $1.07 Million
Q4 2020 Feb 16, 2021	BUY	$75.23 - $109.23 $350,045 - $508,247	4,653 New	4,653 $473,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.